我的京畿瘤科路：在阴阳气血间，寻战癌之刃

我常常想，我这条从河北涿鹿乡间走到京畿之地的行医路，起点或许并非在医学院的课堂，而在更早之前——在跟随舅公（舅爷）于乡野间辨识百草的年岁里，在爷爷舌下取栓，明辨阴阳（金精玉液二穴）的教诲中，在《黄帝内经》那句“正气存内，邪不可干”第一次撞入心扉的瞬间。后来医学院校毕业10余年后，我系统师从首都医科大学附属北京中医医院肝病科陈勇主任，有幸成为国医大师关幼波、焦树德学术思想的第三代传人。前辈们将“十纲辨证”与“治病重脾肾”的思想刻入我的临证血脉，但我深知，面对“癌”这座当代医学的险峰，仅有传承远远不够，必须在亘古的智慧与残酷的现实之间，劈开一条自己的路。

这条路的第一块里程碑，立在2015年。那一年，我发明的“治疗肺癌的中药三花五子六白散”获得了国家发明专利授权。这个方子的源头，可追溯至2005年秋在石家庄的一次偶然机缘，我从一位山东平原县民间抗癌中医处得见清代《方外奇方》所载的“青龙丸”。古方精悍，如一把尘封的利剑。我依循自己的理解，以藏雪莲花、金银花、藏红花为“三花”清解热毒，以五倍子、葶苈子等“五子”与白术、白花蛇舌草等“六白”共奏化痰散结、健脾祛湿之功，再加入全蝎、蜈蚣等虫类药深入络脉，攻坚剔邪。这是我的第一次系统“亮剑”，我希望它能成为刺向肺癌的一柄复合式兵器。

然而，现实的复杂性很快让我意识到，单一兵器的胜利是脆弱的。我发表于2017年的《古方青龙丸治疗中晚期肺癌20例》可视为一次实战记录，但更深的触动来自其后：古方中某些确有疗效但具毒性的药材，在今日严格的药事管理下已难觅踪影；一些曾被奉为“消瘤圣药”的药材，也因种种原因被从现行《药典》中移出。古人构筑的“三驾马车”阵型，在现代语境下骤然损折其二。这并非个例，它尖锐地揭示了一个核心困境：许多蕴藏古人智慧的验方，因药材变迁、理论隔膜，其效能正在不断“衰减”。固守一方便是坐以待毙，我由此转入更为浩繁的求索。

于是，我开始了近乎贪婪的阅读与整合。从金元四家到明清温病，从伤寒经方到民间土法，我的读书笔记积攒了尺许之厚。我系统研读国医大师周仲瑛教授“复法大方”治疗肿瘤的思想，其针对复杂病机、多重证候而灵活组方的策略，让我深受启发。这不是简单的叠加，而是有机的化合。我将这些年总结的多位国医大师如周仲英、周岱翰、刘尚义的治癌观点，加以体悟，连同二十余年临床所见的病例，熔铸于一炉，终于在2021年完成了《梁世杰中医肿瘤治疗学》一书（获国家版权登记）。书中没有神化任何一个“秘方”，而是老老实实整理了针对三十余种常见癌症的数十首专病专方，它们来自古籍、来自名家、也来自我个人临床化裁的总结。我的目的，是试图为后来者搭建一个更具操作性的“武器库”，而我自己，则必须向前再探一步，去思考这些武器背后的通用战法。

这便是“平秘阴阳，祛邪解毒”八字理论的由来。它源自我对癌症本质的观察，我将其特性归纳为五：潜伏性、猛烈性、顽固性、流注性、伤正性。这五大特性，如同一幅完整的癌病演进图。“潜伏性”对应《内经》“邪之所凑，其气必虚”，是正气亏虚，邪气内伏；“伤正性”则是癌毒肆虐，耗伤气血阴阳的结果。因此，治疗绝不能是“头痛医头”的局部清剿。我的核心思路在于“平秘阴阳”——通过调和脏腑、补益气血，重建人体内环境的稳定与平衡，如同巩固一座城池的防御。在此基础之上，再以“祛邪解毒”为矛，用清热解毒、化痰散结、活血化瘀之法，精准打击癌毒。

我尤为关注“癌前病变”这一关键窗口期。例如，面对西医认为逆转困难的“萎缩性胃炎伴重度肠化生”，我常以《伤寒论》大柴胡汤为基础进行加味，疏利肝胆、通泻脾胃郁热。不少患者在调理后，胃肠镜复查可见明显改善。对于越来越多的“肺结节”人群，我亦依据辨证，采用软坚散结、宣肺通络的方药干预，许多患者的结节得以控制或缩小。这些实践让我坚信，中医的“治未病”思想在肿瘤防治链的前端，拥有不可替代的战略价值。

然而，理论与临床之间，横亘着巨大的信任鸿沟。我深知，在肿瘤这样的领域，空谈理论无异于纸上谈兵。因此，我给自己和团队立下了一条铁律：追求确定性的疗效。我对医学界那句著名的“有时去治愈，常常去帮助，总是去安慰”持有保留态度。这句话在临终关怀中充满人文温度，但若将其泛化为整个医疗行为的“挡箭牌”，则可能消解医生追求治愈技术的根本动力。《灵枢·邪气脏腑病形》将医生分为上工、中工、下工，其标准是“十全九”、“十全七”、“十全六”的治愈率。我认为，一名合格的中医，至少应力求“十全六”的基准。这意味着，我们必须让治疗方案在患者身上产生可感知的积极变化——疼痛减轻、食欲恢复、体力增加、影像学稳定甚至好转。

为此，我积极借鉴现代医学的评价体系。例如，在针对晚期非小细胞肺癌的联合治疗中，参考类似“参术扶正抗癌汤”联合放化疗的临床研究思路，我们在扶正祛邪方剂的应用中，不仅关注症状改善，也会参考患者卡氏评分（KPS）的生活质量变化，乃至血清肿瘤标志物、T细胞亚群等免疫指标的动态。这不是“中医西化”，而是为了让古老医学的疗效，能在一个更广谱的语境下被清晰认知与验证。当一位被预估生存期仅数月的晚期患者，通过中药调理实现了长期“带瘤生存”，且生活质量尚可时，那份生命的尊严，便是对这套战法最有力的注脚。

从河北基层卫生院到立足北京，我这二十年的“京畿”行医路，看的虽非全是肿瘤，但重症大病最为刻骨铭心。我把自己逼成了一个“杂家”，也逼着中医肿瘤学思考更根本的问题。肿瘤治疗，是一场发生在人体内部微小宇宙的残酷战争。我所致力的，是运用中医的系统观，努力理解这个宇宙失衡的法则（病机），然后以草木金石为兵将，以复方大方为阵图，以“平秘阴阳”筑城墙，以“祛邪解毒”出奇兵。

路漫漫其修远。古方或许会蒙尘，药材或许会变迁，但中医认识生命、调和阴阳的哲学内核历久弥新。我辈所能做，亦所当做的，便是做一个诚实的“修路工”与“实战者”，在经典与现代、坚守与创新之间，为更多在黑暗中跋涉的生命，凿刻出一级级可供攀援的台阶。这，便是我自居“京畿瘤科”的全部初衷与求索。

作者简介：梁世杰 原首都医科大学中医门诊部中医主治医师，京畿瘤科创始人，本科学历，从事中医临床工作25年，积累了较丰富的临床经验。师从首都医科大学附属北京中医院肝病科主任医师、著名老中医陈勇，侍诊多载，深得器重，尽得真传！擅用“商汤经方分类疗法”、专病专方结合“焦树德学术思想”“关幼波十纲辨证”学术思想治疗疑难杂症为特色。现任北京树德堂中医研究院研究员，北京中医药薪火传承新3+3工程—焦树德门人（陈勇）传承工作站研究员，国际易联易学与养生专委会常务理事，中国中医药研究促进会焦树德学术传承专业委员会委员，中国药文化研究会中医药慢病防治分会首批癌症领域入库专家。荣获2020年中国中医药研究促进会仲景医学分会举办的第八届医圣仲景南阳论坛“经方名医”荣誉称号。2023年首届京津冀“扁鹊杯”燕赵医学研究主题征文优秀奖获得者。事迹入选《当代科学家》杂志、《中华英才》杂志。

My path in the field of gynecological oncology: Navigating between yin, yang, qi, and blood to seek the blade that can combat cancer.

Often, I think about my journey as a practitioner, which began in the countryside of Zhuolu, Hebei Province, and eventually led me to the heart of the capital region. Perhaps this journey did not start in the classrooms of a medical school, but rather much earlier – during my years of accompanying my maternal grandfather (my great-grandfather) in the fields to identify various herbs, learning from him about removing blockages from under my great-grandfather’s tongue and understanding the principles of yin and yang (the acupoints of Jinjin and Yuye) from my grandfather’s teachings. It was during that moment when I first grasped the phrase from the Huangdi Neijing, “The righteous qi resides within; the evil cannot affect it.” After completing my studies in a medical school more than a decade later, I formally studied under Chen Yong, the director of the Hepatology Department at Beijing Hospital Affiliated to Capital Medical University. I was fortunate to become the third generation of disciples for the scholarly ideas of Guo Youbo and Jiao Shu-de, the masters of traditional Chinese medicine. The elders instilled in me the concepts of the “Ten Principles of Diagnosis” and the importance of treating diseases by strengthening the spleen and kidneys. However, I am well aware that, in the face of the formidable challenges posed by “cancer,” mere inheritance is not enough; one must carve out one’s own path between ancient wisdom and harsh reality.

The first milestone on this road was established in 2015. That year, my invention, “Treatment of Lung Cancer with Traditional Chinese Medicine: Sanhua Wu Zi Li Bai San,” received a national invention patent. The origins of this formula can be traced back to an accidental encounter in Shijiazhuang in the autumn of 2005, where I came across the “Qinglong Pill” described in the Qing Dynasty’s “Fang Wai Qi Fang.” This ancient formula is powerful, akin to a long-forgotten sword. Based on my understanding, I used Snow Lotus Flower, Forsythia, and Saffron as the “three flowers” to clear heat and detoxify, combined with “five seeds” such as Euphorbia cerifera and “six whites” like Atractylis lanceolata and Scutellaria barbata to promote expectoration, resolve phlegm, tonify the spleen, and remove dampness. I then added insects like Scorpion and Centipede to penetrate the network of blood vessels and eliminate pathogenic factors. This was my first systematic “sword-wielding” effort, and I hoped it would become a composite weapon aimed at lung cancer.

However, the complexities of reality soon made me realize that the victory of a single weapon was fragile. My publication in 2017, “The Treatment of 20 Cases of Advanced Lung Cancer with Ancient Formula Qinglong Pill,” can be seen as a record of a real-world experiment. But what struck me even more profoundly was the fact that certain herbs in ancient formulas, which were indeed effective but also toxic, are now difficult to find under today’s stringent pharmaceutical regulations. Some herbs once revered as “miracle cures for tumors” have also been removed from the current Pharmacopoeia for various reasons. The “three-horse carriage” formation devised by the ancients has suddenly lost two of its components in modern contexts. This is not an isolated case; it starkly reveals a core dilemma: many formulas that embody the wisdom of the ancients are experiencing a continuous “decline” in efficacy due to changes in herbs and theoretical gaps. Sticking to one approach is tantamount to waiting for disaster to strike; this prompted me to embark on a more extensive quest.

As a result, I embarked on an almost voracious process of reading and integration. From the Four Great Masters of Jin Yuan to the Ming and Qing Dynasties’ studies on febrile diseases, from the classical prescriptions of the Treatise on Febrile and Miscellaneous Diseases to folk remedies, my reading notes accumulated to the thickness of a few inches. I systematically studied Professor Zhou Zhongying’s ideas on using “reformulated formulas” to treat tumors, which emphasized the flexibility of formulating treatments based on complex pathological mechanisms and multiple syndromes. This approach greatly inspired me. It was not simply about adding things together; it was about forming an organic whole. I synthesized the cancer-fighting perspectives of various renowned Chinese medical masters, such as Zhou Zhongying, Zhou Daihan, and Liu Shangyi, along with the clinical cases I observed over twenty years. Finally, in 2021, I completed the book “Liang Shijie’s Chinese Cancer Treatment” (which has been registered for national copyright). The book does not glorify any “secret formulas”; instead, it meticulously presents dozens of specialized formulas tailored for over thirty common types of cancer, derived from ancient texts, masterworks, and my own clinical adaptations. My goal was to create a more practical “weapons arsenal” for future practitioners, while I myself had to venture further ahead to contemplate the underlying universal strategies behind these weapons.

This is the origin of the eight-character theory of “balancing Yin and Yang, dispelling evil and detoxifying.” It stems from my observations of the nature of cancer, which I have summarized into five characteristics: latent, intense, stubborn, flowing, and damaging to the vital forces. These five characteristics form a comprehensive picture of the progression of cancer. “Latent” corresponds to the concept in the “Inner Canon” that “where there is an accumulation of evil, the corresponding qi will be deficient,” indicating a state of deficiency of vital qi and the presence of hidden evils. “Damaging to the vital forces” represents the rampant spread of cancer toxins, leading to the depletion of qi, blood, and yin and yang. Therefore, treatment must not be a localized effort of “treating the head when there’s a headache.” My core approach is “balancing Yin and Yang” – by harmonizing the organs, replenishing qi and blood, and restoring the stability and balance of the human body’s internal environment, akin to fortifying a city’s defenses. On this foundation, we can then use “dispelling evil and detoxifying” as our weapon, employing methods such as clearing heat and detoxifying, resolving phlegm and knots, and promoting blood circulation to precisely target and eliminate cancer toxins.

I pay particular attention to the critical window period for “pre-cancerous lesions.” For example, when dealing with “atrophic gastritis with severe metaplasia,” which Western medicine considers difficult to reverse, I often base my treatment on the Da-Xiao-Bu Decoction from “Treatise on Febrile and Miscellaneous Diseases” and use it to promote the flow of bile and gallbladder, and to clear the stagnation of heat in the spleen and stomach. After undergoing treatment, many patients have seen significant improvements in their results from gastrointestinal endoscopies. For the growing number of individuals with “lung nodules,” I also use diagnostic methods to intervene with formulas that soften hard masses, disperse adhesions, and promote lung function and blood circulation. Many of these patients have been able to control or reduce the size of their nodules. These experiences have convinced me that the concept of “preventive medicine” in traditional Chinese medicine holds irreplaceable strategic value at the forefront of the cancer prevention and treatment chain.

However, there exists a significant gap of trust between theory and clinical practice. I am well aware that in fields like oncology, mere theoretical discussions are akin to mere speculation. Therefore, I have established a firm rule for myself and my team: to pursue definitive and effective results. I have reservations about the famous phrase in medicine, “Sometimes to cure, often to alleviate, always to comfort.” This phrase is imbued with humanistic warmth in palliative care, but if it is generalized as a “shield” for the entire realm of medical practice, it may undermine the fundamental motivation of doctors to pursue curative techniques. The “Xue Li” text, which categorizes doctors into superior, intermediate, and inferior practitioners based on their cure rates of “ten complete cases out of ten,” “nine complete cases out of ten,” and “six complete cases out of ten,” respectively, suggests that a competent traditional Chinese medicine practitioner should strive to achieve the benchmark of “six complete cases out of ten.” This implies that we must ensure that our treatment plans lead to perceptible positive changes in patients – reduced pain, restored appetite, increased physical strength, stable or even improving imaging results.

To this end, I actively draw inspiration from the evaluation systems of modern medicine. For example, in the context of combined treatment for advanced non-small cell lung cancer, we reference clinical research approaches similar to those involving the combination of “San-Shu Fu-Zheng Anti-Cancer Decoction” with radiotherapy and chemotherapy. In the application of tonifying and eliminating malignancy formulas, we not only focus on symptom improvement but also consider changes in the patient’s Karnofsky Performance Status (KPS) for quality of life, as well as dynamic indicators such as serum tumor markers and T-cell subsets. This is not about “Westernizing traditional Chinese medicine”; rather, it is about allowing the efficacy of ancient medicine to be clearly understood and validated within a broader context. When a patient with advanced cancer, whose estimated survival time was only a few months, achieved long-term “tumor-bearing survival” through herbal therapy and maintained a relatively good quality of life, the dignity of that life serves as the strongest testament to this approach.

From the grassroots health clinics in Hebei Province to establishing a foothold in Beijing, my twenty-year journey as a practitioner in the “capital region” has involved treating a variety of conditions, although not exclusively tumors. However, the treatment of severe and critical illnesses has been the most memorable. I have pushed myself to become a “jack-of-all-trades” and have compelled traditional Chinese medicine oncology to consider more fundamental issues. Tumor treatment is a brutal war taking place within the microscopic universe of the human body. What I strive to do is to apply the systemic view of traditional Chinese medicine, strive to understand the laws governing this cosmic imbalance (pathogenesis), then use herbs, minerals, and stones as soldiers, employ compound formulas as battle plans, build walls with the principles of balancing yin and yang, and employ unconventional tactics to eliminate evil and detoxify.

The path ahead is long and arduous. Ancient methods may become obscured, ingredients may change, but the philosophical core of traditional Chinese medicine’s understanding of life and the harmonization of yin and yang remains vibrant and ever-relevant. What we can and should do is to be honest “road workers” and “practitioners,” bridging the gap between classics and modernity, adhering to tradition while embracing innovation, and carving out steps that others can climb in the darkness. This is the very purpose and pursuit that drives me to identify myself as a practitioner of “the Beijing Tumor Clinic.”

Author profile: Liang Shi-jie was a chief physician of traditional Chinese medicine at the Traditional Chinese Medicine Outpatient Clinic of Capital Medical University. He was the founder of Jingyi Tumor Clinic. He holds a bachelor’s degree and has been engaged in clinical work in traditional Chinese medicine for 25 years, accumulating extensive clinical experience. He studied under Chen Yong, a renowned senior traditional Chinese medicine practitioner at the Hepatology Department of Beijing Traditional Chinese Medicine Hospital affiliated to Capital Medical University. Over the years, he gained great respect and acquired genuine expertise. He specializes in using the “Shang Tang Classic Classification Therapy” and combining specific treatments for specific diseases with the “Jiao Shu-de Academic Thought” and the “Guan You-bo Ten-Principle Diagnosis” approach to treat complex medical conditions. He is currently a researcher at the Beijing Shu-de-Tang Traditional Chinese Medicine Research Institute and a researcher at the Beijing New 3+3 Project for the Inheritance of Traditional Chinese Medicine – Jiao Shu-de’s Disciples (Chen Yong) Heritage Workstation. He is a Standing director of the International Yi-lian Yi-xue and Health Preservation Committee and a member of the Committee for the Inheritance of Jiao Shu-de’s Academic Thought of the China Research Promotion Association for Traditional Chinese Medicine. He is also a member of the inaugural Cancer Expert Pool of the China Cultural Research Association for Traditional Chinese Medicine’s Prevention of Chronic Diseases. He was awarded the title of “Expert in Classic Prescriptions” at the Eighth Nanyang Forum of the Zhang Zhongjing Medical Division of the China Research Promotion Association in 2020. In 2023, he won the Excellence Award in the First Beijing-Tianjin-Hebei “Bian Que Cup” Yan-Zhao Medical Research Theme Essay Competition. His achievements have been featured in the magazines “Contemporary Scientists” and “China’s Elite”.